EI
RPRX

EAM Investors’s Repros Therapeutics Inc. RPRX Stock Holding History

EAM Investors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-95,476
Closed -$2.56M – 432
2013
Q3 		$2.56M Buy
+95,476
New +$2.05M 0.51% 41

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EAM Investors's RPRX Position: Q4 2013 in Review

EAM Investors sold out of Repros Therapeutics Inc. (RPRX) in Q4 2013, closing a stake of 95,476 shares — an estimated $2.56M sold.

EAM Investors first reported a position in RPRX in Q3 2013 and held it in 1 quarter. The position peaked at $2.56M in Q3 2013. 79 funds tracked by Wall St. Rank hold RPRX as of Q4 2013.

  • EAM Investors reported no remaining Repros Therapeutics Inc. position as of Q4 2013 after selling out during the quarter.
  • EAM Investors sold 95,476 Repros Therapeutics Inc. shares in Q4 2013, an estimated $2.56M.
  • EAM Investors first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 1 quarter.
  • EAM Investors's Repros Therapeutics Inc. position peaked at $2.56M in Q3 2013.
  • 79 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2013.

Based on EAM Investors's 13F filing for Q4 2013, filed 14 Feb 2014.